A world of information in every drop

Harnessing the power of DNA
from a single blood sample to improve
the management of reproductive
health, cancer, and organ transplants.

A world of information in every drop

Harnessing the power of DNA
from a single blood sample to improve
the management of reproductive
health, cancer, and organ transplants.

A world of information in every drop

Harnessing the power of DNA
from a single blood sample to improve
the management of reproductive
health, cancer, and organ transplants.

A world of information in every drop

Harnessing the power of DNA
from a single blood sample to improve
the management of reproductive
health, cancer, and organ transplants.

A world of information in every drop

Harnessing the power of DNA
from a single blood sample to improve
the management of reproductive
health, cancer, and organ transplants.

Horizon^™

Advanced carrier
screening

Spectrum^®

Preimplantation
genetics

Panorama^®

Next-generation
NIPT

Vistara

Single-gene
NIPT

Anora^®

Miscarriage
test (POC)

Evercord^™

Newborn stem
cell banking

Signatera^™

Research use
only

In the news

April 17, 2019

Natera Announces Pricing of Follow-On Offering

April 16, 2019

New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer

April 10, 2019

Natera Announces Plans to Commercialize Tumor Whole Exome Sequencing from Plasma

March 28, 2019

Medicare Issues Draft Local Coverage Determination for Natera's New Prospera™ Kidney Transplant Rejection Test

March 26, 2019

Natera to Partner with AMAL Therapeutics on Clinical Trial Using Signatera MRD Test to Assess Treatment Response to Colorectal Cancer Vaccine

March 12, 2019

Natera Reports Fourth Quarter and Fiscal Year 2018 Financial Results

March 11, 2019

Natera and BGI Genomics Announce $50M Partnership to Commercialize Signatera Oncology Test in China and to Develop Reproductive Health Tests in Select Markets on BGI's DNBseq™ Technology Platform

March 5, 2019

Natera, Inc. Announces Fourth Quarter and Fiscal 2018 Earnings Conference Call

February 22, 2019

Natera Announces Publication of Analytical Validation Study Demonstrating Superior Precision of Its Kidney Transplant Rejection Assay

February 19, 2019

Natera Presents Outcomes Data at SMFM Annual Meeting Showing Strong Clinical Performance of Its SNP-Based Non-Invasive Prenatal Test

February 1, 2019

Natera Announces Agreement with One Lambda to Co-Distribute Its Kidney Transplant Rejection Test

January 7, 2019

Natera Announces Publication of Kidney Transplant Validation Study, Demonstrating Superior Data in Detection of Clinical and Subclinical Rejection

January 4, 2019

Natera To Webcast Live Presentation at the 37th Annual J.P. Morgan Healthcare Conference

January 4, 2019

Natera Obtains Z-Codes for Signatera MRD and Treatment Monitoring Test in Oncology

January 2, 2019

Natera Appoints Steve Chapman CEO and Robert Schueren COO; Matthew Rabinowitz Moves to Executive Chairman

December 6, 2018

Natera Presents Breast Cancer Data at SABCS Showing Ability of Signatera (RUO) to Detect Molecular Residual Disease Up to Two Years Prior to Clinical Relapse and Predict Treatment Response

November 29, 2018

Natera Achieves Enrollment Goal of 20,000 Patients in SMART Study

November 28, 2018

Natera Receives Unique Z-Code for Its Kidney Transplant Rejection Monitoring Test

November 8, 2018

Natera Reports Third Quarter 2018 Financial Results

October 18, 2018

Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine

September 13, 2018

Natera Signs Agreement with Bristol-Myers Squibb

July 12, 2018

Natera Announces Pricing of Follow-On Offering

June 21, 2018

Natera Develops Powerful Kidney Transplant Rejection Biomarker

June 19, 2018

Natera and Institut Jules Bordet Announce Collaboration in Neoadjuvant Breast Cancer

June 13, 2018

Natera Announces New Clinical Utility Data and Issuance of CPT Code for NIPT in Twin Pregnancies

Family of reproductive health genetic tests

Natera^® is driven by a passion for improving the path to parenthood with a suite of high-quality products that support families in their journey from preconception, to pregnancy, and birth.

LEARN MORE

Family of reproductive health genetic tests

Natera^® is driven by a passion for improving the path to parenthood with a suite of high-quality products that support families in their journey from preconception, to pregnancy, and birth.

LEARN MORE

Family of reproductive health genetic tests

Natera^® is driven by a passion for improving the path to parenthood with a suite of high-quality products that support families in their journey from preconception, to pregnancy, and birth.

LEARN MORE

Family of reproductive health genetic tests

Natera^® is driven by a passion for improving the path to parenthood with a suite of high-quality products that support families in their journey from preconception, to pregnancy, and birth.

LEARN MORE

Family of reproductive health genetic tests

Natera^® is driven by a passion for improving the path to parenthood with a suite of high-quality products that support families in their journey from preconception, to pregnancy, and birth.

LEARN MORE

Applying revolutionary technology to change the management of disease worldwide is at the heart of Natera’s mission.

Cutting-edge
oncology research

Natera is developing new tools to revolutionize treatment monitoring, recurrence monitoring, and residual disease detection across many cancer types.

LEARN MORE

Cutting-edge
oncology research

Natera is developing new tools to revolutionize treatment monitoring, recurrence monitoring, and residual disease detection across many cancer types.

LEARN MORE

Cutting-edge
oncology research

Natera is developing new tools to revolutionize treatment monitoring, recurrence monitoring, and residual disease detection across many cancer types.

LEARN MORE

Cutting-edge
oncology research

Natera is developing new tools to revolutionize treatment monitoring, recurrence monitoring, and residual disease detection across many cancer types.

LEARN MORE

Cutting-edge
oncology research

Natera is developing new tools to revolutionize treatment monitoring, recurrence monitoring, and residual disease detection across many cancer types.

LEARN MORE